Second Booster Dose Authorized to Up Protection Against COVID-19 for Certain People
The Emergency Use Authorization was based on safety and immunogenicity data provided to the Agency.
The Emergency Use Authorization was based on safety and immunogenicity data provided to the Agency.
Several pharmacotherapies have been shown to reduce pain in patients with painful diabetic neuropathy.
The CDC is recommending that health care providers take a travel history for all suspected and confirmed cases of COVID-19.
The researchers examined data from the National Health and Nutrition Examination Survey.
The study authors conducted a nationwide cohort study that included 137,667 Medicare beneficiaries.
The CDC recommendations also allow for the use of a heterologous (or “mix and match”) booster dose.
The decision comes following the results of two FDA advisory committee meetings.
Routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications.
The sNDA is supported by data from the phase 3 COSMIC-311 study.
The BLA submission is based on positive results across four phase 3 studies in wet AMD and DME.